News Quantified

IFRX – inflarx n.v. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome [Yahoo! Finance]

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

InflaRx Reports Q3 2024 Financial Results and Progress [Yahoo! Finance]

InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

2.0%

MISS

-5.0%

MISS

0.0%

BEAT

Form 6-K InflaRx N.V. For: Nov 15

Form 6-K InflaRx N.V. For: Nov 08

Top News Gainers

3/31 InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx’s anti-C5a Technology 50.0%

4/29 Form 20-F InflaRx N.V. For: Dec 31 30.0%

2/14 Form SC 13G/A InflaRx N.V. Filed by: Cormorant Asset Management, LP 23.6%

2/19 InflaRx to Present at Upcoming SVB Leerink Global Healthcare Conference 14.9%

2/26 Form 6-K InflaRx N.V. For: Feb 26 14.1%

6/12 Inflarx NV (NASDAQ: IFRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.75 price target on the stock. 6.1%

1/8 Inflarx NV (NASDAQ: IFRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.00 price target on the stock. 5.2%

10/23 Inflarx NV (NASDAQ: IFRX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 4.9%

6/14 Form 6-K InflaRx N.V. For: Jun 14 4.7%

6/13 InflaRx Treats First Patient in Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum 3.6%

Top News Decliners

6/5 Form 6-K InflaRx N.V. For: Jun 05 -91.8%

4/1 Form 6-K InflaRx N.V. For: Mar 31 -34.4%

3/2 Form 6-K InflaRx N.V. For: Mar 02 -23.5%

11/7 Form 6-K InflaRx N.V. For: Nov 07 -21.7%

7/18 Form 6-K InflaRx N.V. For: Jul 18 -16.0%

5/23 Form 6-K InflaRx N.V. For: May 23 -10.2%

4/29 InflaRx Reports Full Year 2019 Financial & Operating Results -7.8%

11/14 Form 6-K InflaRx N.V. For: Nov 14 -5.3%

4/9 Form 6-K InflaRx N.V. For: Apr 09 -3.1%

2/26 InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum -3.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day